This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging
- Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab
- Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response
- Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma
- Blood-Based Red Marrow Dosimetry: Where's the Beef?
- Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen
- Bone Marrow Dosimetry Using Blood-Based Models for Radiolabeled Antibody Therapy: A Multiinstitutional Comparison
- Red Marrow Radiation Dose Adjustment Using Plasma FLT3-L Cytokine Levels: Improved Correlations Between Hematologic Toxicity and Bone Marrow Dose for Radioimmunotherapy Patients
- Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy
- Evaluation of Limited Blood Sampling in a Preceding 99mTc-Labeled Diagnostic Study to Predict the Pharmacokinetics and Myelotoxicity of 186Re-cMAb U36 Radioimmunotherapy
- Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application